AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and OccupationsAnthropology, Education, Sociology and Social PhenomenaHumanitiesInformation ScienceHealth Care
Antineoplastic Combined Chemotherapy ProtocolsCyclophosphamideAntineoplastic AgentsCombined Modality TherapyDoxorubicinChemotherapy, AdjuvantCisplatinDisease-Free SurvivalTreatment OutcomeMitoxantroneVincristinePrognosisOsteosarcomaDrug Administration ScheduleEtoposideCytarabineMethotrexatePaclitaxelVindesineMelphalanPrecursor Cell Lymphoblastic Leukemia-LymphomaSurvival RateBreast NeoplasmsBleomycinGranulocyte Colony-Stimulating FactorLymphoma, Non-HodgkinTransplantation, AutologousLung NeoplasmsEpirubicinRemission InductionRetrospective StudiesHematopoietic Stem Cell TransplantationNeoadjuvant TherapySurvival AnalysisNeoplasm StagingNeoplasmsAntibiotics, AntineoplasticAntineoplastic Agents, PhytogenicAntimetabolites, AntineoplasticAntineoplastic Agents, AlkylatingFluorouracilCarboplatinVinblastineClinical ProtocolsDrug Resistance, NeoplasmTaxoidsBone Marrow TransplantationPrednisoneInduction ChemotherapyTime FactorsIfosfamideNeoplasm Recurrence, LocalDeoxycytidineOrganoplatinum CompoundsAnthracyclinesOvarian NeoplasmsFollow-Up StudiesCell Line, TumorCarcinoma, Non-Small-Cell LungNeoplasm MetastasisVomitingAdenocarcinomaNauseaSalvage TherapyChemotherapy, Cancer, Regional PerfusionNeutropeniaClinical Trials as TopicDose-Response Relationship, DrugCarmustineRadiotherapyColorectal NeoplasmsCamptothecinProspective StudiesInfusions, IntravenousTesticular NeoplasmsDaunorubicinRadiotherapy, AdjuvantBrain NeoplasmsLomustineDacarbazineApoptosisHodgkin DiseaseDrug Screening Assays, AntitumorMitomycinLeukopeniaBone NeoplasmsRadiotherapy DosageLiver NeoplasmsKaplan-Meier EstimateNeoplasms, Germ Cell and EmbryonalAntibodies, Monoclonal, HumanizedDrug SynergismTumor Markers, BiologicalInfusions, Intra-ArterialPlatinum CompoundsRecurrenceRandomized Controlled Trials as TopicAntiemeticsTumor Cells, CulturedLymphoma
RadiotherapyHigh-dose methotrexate and cytarabineEverolimusRegimenAcute myeloidCytarabineNeuroendocrine tumorsAdjuvantPancreaticMaximum Tolerated DoseTherapyToxicitiesIndicationsDoxorubicinIntravenousSurvivalToxicityInfusionTreatmentCumulative doseInstitutional protocolAgentsPatientsOccurDrugAgentStudyPatientCellAnalysisReferComplexBlood
Radiotherapy4
  • Compliance was good with 93 and 89% of patients completing radiotherapy and chemotherapy, respectively. (ox.ac.uk)
  • Since photodynamic therapy (PDT) does not compromise other treatment options and presents reduced long-term morbidity when compared with chemotherapy or radiotherapy, it appears as a promising alternative treatment for controlling malignant diseases. (oaepublish.com)
  • The combination therapy is able to remarkably enhance effect of chemotherapy or radiotherapy, prevent and minimize toxic side effect of these therapies and raise resection rate in operation. (kanglaite.com)
  • Although surgery and radiotherapy achieves cure in a high percentage of patients with early-stage SCCHNs, conventional treatment does not achieve cure for the majority of those with locally advanced disease, and treatment for recurrent disease with chemotherapy is far from satisfactory. (entokey.com)
High-dose methotrexate and cytarabine2
Everolimus1
  • accepted choices are somatostatin analogs, peptide receptor radionuclide therapy, everolimus and chemotherapy. (springeropen.com)
Regimen4
  • At 6 months, event-free survival in these patients, whose prognosis was unfavorable, was 65% with temsirolimus versus 50% with bevacizumab, when these agents were added to a chemotherapy regimen of vinorelbine and cyclophosphamide. (medscape.com)
  • However, the regimen containing irinotecan resulted in a lower rate of hematologic toxicity and cumulative dose of cyclophosphamide. (medscape.com)
  • The predominant regimen was the weekly/bi-weekly intravenous administration of STZ combined with other oral anticancer agents. (cancerindex.org)
  • 40 mg/m 2 on day 1 and 30 mg/m 2 on day 8 every 28 days (as part of the VCAP-AMP-VECP multiagent chemotherapy regimen) for 6 cycles (Tsukasaki 2007). (medilib.ir)
Acute myeloid1
  • PRIMARY OBJECTIVES: I. Determine maximum tolerated dose (MTD) of MEK162 (MEK inhibitor MEK162 ) in patients with RAS-mutated acute myeloid leukemia ( AML ) when combined with sequential induction chemotherapy (3 +4 ) as measured by development of grade 3-4 dose-limiting toxicities (DLT). (mycancergenome.org)
Cytarabine2
  • This phase I trial studies the MEK inhibitor MEK162 to see if it is safe in patients when combined with idarubicin and cytarabine. (mycancergenome.org)
  • Drugs used in chemotherapy, such as idarubicin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. (mycancergenome.org)
Neuroendocrine tumors2
  • Streptozocin chemotherapy for advanced/metastatic well-differentiated neuroendocrine tumors: an analysis of a multi-center survey in Japan. (cancerindex.org)
  • An approved antineoplastic chemotherapy drug used to treat pancreatic neuroendocrine tumors. (letswinpc.org)
Adjuvant1
  • Background: Despite a potentially curative treatment, the prognosis after upfront surgery and adjuvant chemotherapy for patients with resectable pancreatic ductal adenocarcinoma (PDAC) is poor. (unav.edu)
Pancreatic6
  • Chemotherapy with streptozocin (STZ) in combination with 5-FU or doxorubicin (Dox) represents a standard of care for patients with metastatic pancreatic neuroendocrine neoplasms (pNEN). (cancerindex.org)
  • The main recipients of STZ chemotherapy were middle-aged patients with pancreatic NET and unresectable liver metastases. (cancerindex.org)
  • One of the approved chemotherapy drugs for pancreatic cancer, it inhibits cell division and promotes cell death. (letswinpc.org)
  • Pharmacokinetic-guided (PKG) dosing has demonstrated beneficial effects in other tumors, but scarce data is available in pancreatic cancer. (unav.edu)
  • Conclusions: Pharmacokinetically-guided dose adjustment of standard chemotherapy treatments might improve survival outcomes in patients with pancreatic ductal adenocarcinoma. (unav.edu)
  • Also, PKB is overexpressed in 15% of ovarian cancers, 12% of pancreatic cancers and 3% of breast cancers, and was shown to produce a survival signal that protects cells from apoptosis thus contributing to resistance to chemotherapy. (justia.com)
Maximum Tolerated Dose1
  • The objective of this study was to evaluate the maximum tolerated dose (MTD) and recommended dose of irinotecan administered as a 5-day schedule synchronously with 5-fluorouracil (5FU), leucovorin (LV) and preoperative pelvic radiation (45 Gy) for primary borderline/unresectable, locally advanced rectal cancer. (ox.ac.uk)
Therapy7
  • The remaining patients had only minor deviations from protocol therapy. (ox.ac.uk)
  • Additionally, hearing loss may not manifest until several weeks or months after completion of antibiotic or antineoplastic therapy. (medscape.com)
  • In patients with localized disease, overall 5-year survival rates have improved to more than 80% with the combined use of surgery, radiation therapy, and chemotherapy. (medscape.com)
  • Treatment for patients with rhabdomyosarcoma involves a combination of surgery, chemotherapy, and radiation therapy. (medscape.com)
  • Most patients with rhabdomyosarcoma require radiation therapy to achieve adequate local control, though this treatment is not usually performed until after initial surgical resection and the start of chemotherapy. (medscape.com)
  • KLT can be used alone or combined with chemotherapy or radiation therapy or applied peri-operationally. (kanglaite.com)
  • Thus, much effort has been directed toward improvements in primary treatment programs with advances in combined-modality therapy. (entokey.com)
Toxicities1
  • The MTD was determined as the dose causing more than a third of patients to have a dose-limiting toxicity (DLT) defined as specific grade 3 or 4 toxicities. (ox.ac.uk)
Indications1
  • Intra-hepatic chemotherapy for other indications not listed above, including treatment of liver primaries or metastases from other primaries (e.g., breast) besides colorectal cancer. (aetna.com)
Doxorubicin1
  • The risk of cardiomyopathy is proportional to the cumulative exposure with incidences from 1% to 20% for cumulative doses from 300 mg/m 2 to 500 mg/m 2 when doxorubicin is administered every 3 weeks. (medilib.ir)
Intravenous1
  • The study used escalating doses of intravenous irinotecan (6, 8, 10, 12, 14, 16, 18, and 20 mg m(-2)) administered on days 1-5 and 29-33 followed by low dose LV (20 mg m(-2)) and 5FU (350 mg m(-2) over 1 h) in sequential cohorts. (ox.ac.uk)
Survival2
  • It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. (lookformedical.com)
  • Perform preliminary efficacy analysis of combination of MEK162 and induction chemotherapy (3 +4 ) in patients with RAS-mutated AML by measuring complete remission rate, 2-year overall survival, and duration of response. (mycancergenome.org)
Toxicity2
  • The acceptable toxicity and compliance at 18 mg m(-2) recommend testing this dose in future phase III studies. (ox.ac.uk)
  • One third of the patients had at least 1 dose reduction of docetaxel due to toxicity. (unav.edu)
Infusion1
  • Aetna considers intra-hepatic chemotherapy (infusion) medically necessary for members with liver metastases from colorectal cancer. (aetna.com)
Treatment6
  • Combined radiofrequency ablation and PEI for the treatment of HCC. (aetna.com)
  • This phase II study combined elotuzumab (Elo) with carfilzomib, lenalidomide, and dexamethasone (KRd) for treatment of MM in first relapse with the aim of improving efficacy. (bvsalud.org)
  • Streptozocin-Based Chemotherapy in Patients with Advanced Neuroendocrine Neoplasms--Predictive and Prognostic Markers for Treatment Stratification. (cancerindex.org)
  • STZ-based chemotherapy is an effective and well-tolerated treatment option in patients with well differentiated neuroendocrine neoplasms. (cancerindex.org)
  • Treatment with drugs that boost the body's disease-fighting ability (immunotherapy) and drugs that kill fast-growing cells (chemotherapy). (letswinpc.org)
  • Afterwards, tumors at a volume of 0,12 cm³ were randomly allocated in the treatment groups of graded single doses under clamp blood flow conditions inducing homogenous hypoxia. (europdxworkshop.eu)
Cumulative dose1
  • the risk for cardiomyopathy increases as the cumulative dose increases and is also dependent on other/additional risk factors. (medilib.ir)
Institutional protocol1
  • Methods: Forty-six patients with resected PDAC after mFOLFIRINOX neoadjuvant approach and included in an institutional protocol for anticancer drug monitoring were retrospectively analyzed. (unav.edu)
Agents1
  • Such activity would result in increased cell death of tumor tissue where PKB is elevated, and in decreased resistance to chemotherapy agents. (justia.com)
Patients6
  • Once the MTD was reached, a further 14 patients were treated at the dose level below the MTD. (ox.ac.uk)
  • In total, 57 patients received irinotecan at the eight dose levels. (ox.ac.uk)
  • Dose limiting grade 3 or 4 diarrhoea was reported in seven out of 57 patients, three at the 20 mg m(-2) dose level. (ox.ac.uk)
  • The aim of this study was a retrospective evaluation of the clinicopathological characteristics of pNEN patients receiving STZ-based chemotherapies and to identify predictive and prognostic markers. (cancerindex.org)
  • The aim of the present study was to determine the status of STZ usage in Japan and to evaluate the effectiveness and safety of STZ chemotherapy in Japanese NET patients. (cancerindex.org)
  • Sequential IV/PO moxifloxacin communication of patients with severe community-acquired pneumonia order 80mg tadapox amex erectile dysfunction icd 9 code. (mein-schoenefeld.info)
Occur1
  • The usual time of onset is often unpredictable, and marked hearing loss can occur even after a single dose. (medscape.com)
Drug1
  • Overall, our study offers a novel conceptual framework for biomimetic NPs using a DoE strategy and consolidates the high therapeutic potential of leukosomes as a viable drug delivery system for anti-inflammatory and antineoplastic applications. (frontiersin.org)
Agent1
  • It is used as an antineoplastic agent and to induce diabetes in experimental animals. (cancerindex.org)
Study1
  • Five institutions with experience performing STZ chemotherapy participated in the study. (cancerindex.org)
Patient1
  • The patient demographics, tumor characteristics, context of STZ chemotherapy, and patient outcome were collected and assessed. (cancerindex.org)
Cell1
  • Direct correlation between resistance to chemotherapy and activation of PKB was shown in several prostate cancer cell lines and in human tumorogenic tissues, and elevation of PKB levels in prostate tumor tissues, is clinically associated with HRPC (Yongde et al. (justia.com)
Analysis1
  • At 4 cm³ tumor volume (F1) animals were sacrificed and tumors were taken for analysis and sequential transplantation (F2, F3). (europdxworkshop.eu)
Refer1
  • refer to protocol for details (DeAngelo 2015). (medilib.ir)
Complex2
  • Metastasis are characterized by a sequential and complex process during which cancer cells invade specific organs including lung, liver, brain, and bone [ 3 ] . (oaepublish.com)
  • Wound healing is a complex biological process comprised of a series of sequential events aiming to repair injured tissue. (biomedcentral.com)
Blood1
  • Liver and renal function, as well as blood electrolytes and chemistry, must be assessed before chemotherapy. (medscape.com)